Savara Inc.

Industry · 11 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Autoimmune Pulmonary Alveolar Proteinosis	Phase 3	2025-10-22
Active Not Recruiting	Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Autoimmune Pulmonary Alveolar Proteinosis	Phase 3	2021-05-19
Terminated	Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)	Phase 2	2019-06-20
Terminated	Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis	Phase 3	2018-04-16
Completed	Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection Mycobacterium Infections, Nontuberculous	Phase 2	2018-03-01
Completed	AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fib MRSA, Cystic Fibrosis	Phase 3	2017-09-20
Completed	Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis	Phase 2	2016-03-21
Completed	Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis	Phase 1	2015-05-01
Completed	Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis P Cystic Fibrosis	Phase 2	2013-03-01
Completed	Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics Healthy, Cystic Fibrosis	Phase 1	2011-11-01
Available	Molgramostim Nebulizer Solution Expanded Access Program Protocol Autoimmune Pulmonary Alveolar Proteinosis	—	—